Indoco Remedies Limited (INDOCO) - Net Assets

Latest as of September 2025: Rs9.74 Billion INR ≈ $105.37 Million USD

Based on the latest financial reports, Indoco Remedies Limited (INDOCO) has net assets worth Rs9.74 Billion INR (≈ $105.37 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs25.08 Billion ≈ $271.23 Million USD) and total liabilities (Rs15.34 Billion ≈ $165.86 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Indoco Remedies Limited liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs9.74 Billion
% of Total Assets	38.85%
Annual Growth Rate	12.37%
5-Year Change	32.43%
10-Year Change	74.29%
Growth Volatility	20.05

Indoco Remedies Limited - Net Assets Trend (2004–2025)

This chart illustrates how Indoco Remedies Limited's net assets have evolved over time, based on quarterly financial data. Also explore how large is Indoco Remedies Limited's balance sheet for the complete picture of this company's asset base.

Annual Net Assets for Indoco Remedies Limited (2004–2025)

The table below shows the annual net assets of Indoco Remedies Limited from 2004 to 2025. For live valuation and market cap data, see how much is Indoco Remedies Limited worth.

Year	Net Assets	Change
2025-03-31	Rs10.18 Billion ≈ $110.13 Million	-8.30%
2024-03-31	Rs11.10 Billion ≈ $120.10 Million	+8.00%
2023-03-31	Rs10.28 Billion ≈ $111.20 Million	+13.66%
2022-03-31	Rs9.05 Billion ≈ $97.83 Million	+17.64%
2021-03-31	Rs7.69 Billion ≈ $83.16 Million	+13.16%
2020-03-31	Rs6.80 Billion ≈ $73.49 Million	+2.87%
2019-03-31	Rs6.61 Billion ≈ $71.44 Million	-2.13%
2018-03-31	Rs6.75 Billion ≈ $73.00 Million	+3.60%
2017-03-31	Rs6.52 Billion ≈ $70.46 Million	+11.51%
2016-03-31	Rs5.84 Billion ≈ $63.19 Million	+12.63%
2015-03-31	Rs5.19 Billion ≈ $56.11 Million	+13.43%
2014-03-31	Rs4.57 Billion ≈ $49.47 Million	+10.47%
2013-03-31	Rs4.14 Billion ≈ $44.78 Million	+7.61%
2012-03-31	Rs3.85 Billion ≈ $41.61 Million	+9.87%
2011-03-31	Rs3.50 Billion ≈ $37.87 Million	+12.78%
2010-03-31	Rs3.11 Billion ≈ $33.58 Million	+11.52%
2009-03-31	Rs2.78 Billion ≈ $30.11 Million	+9.52%
2008-03-31	Rs2.54 Billion ≈ $27.50 Million	+9.11%
2007-03-31	Rs2.33 Billion ≈ $25.20 Million	+17.46%
2006-03-31	Rs1.98 Billion ≈ $21.45 Million	+13.16%
2005-03-31	Rs1.75 Billion ≈ $18.96 Million	+99.20%
2004-03-31	Rs880.11 Million ≈ $9.52 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Indoco Remedies Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 672165100000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Retained Earnings	Rs6.72 Billion	65.77%
Common Stock	Rs184.50 Million	1.81%
Other Comprehensive Income	Rs2.65 Billion	25.91%
Other Components	Rs665.57 Million	6.51%
Total Equity	Rs10.22 Billion	100.00%

Indoco Remedies Limited Competitors by Market Cap

The table below lists competitors of Indoco Remedies Limited ranked by their market capitalization.

Company	Market Cap
Vestel Elektronik Sanayi ve Ticaret AS IS:VESTL	$208.87 Million
Smartbroker Holding AG XETRA:SB1	$208.93 Million
Bank Amar Indonesia JK:AMAR	$208.99 Million
Namyang Dairy KO:003920	$209.00 Million
GOLFZON Co. Ltd KQ:215000	$208.77 Million
Taiwan Fu Hsing Industrial Co Ltd TW:9924	$208.75 Million
AC IMMUNE SA SF-02 F:IMR	$208.75 Million
Investcorp Europe Acquisition I Corp NASDAQ:IVCB	$208.74 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Indoco Remedies Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 11,099,001,000 to 10,220,000,000, a change of -879,001,000 (-7.9%).
Net loss of 737,400,000 reduced equity.
Dividend payments of 139,000,000 reduced retained earnings.
Share repurchases of 15,900,000 reduced equity.
New share issuances of 15,900,000 increased equity.
Other comprehensive income increased equity by 28,835,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs-737.40 Million	-7.22%
Dividends Paid	Rs139.00 Million	-1.36%
Share Repurchases	Rs15.90 Million	-0.16%
Share Issuances	Rs15.90 Million	+0.16%
Other Comprehensive Income	Rs28.84 Million	+0.28%
Other Changes	Rs-31.44 Million	-0.31%
Total Change	Rs-	-7.92%

Book Value vs Market Value Analysis

This analysis compares Indoco Remedies Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.76x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 15.75x to 1.76x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2004-03-31	Rs13.30	Rs209.49	x
2005-03-31	Rs22.91	Rs209.49	x
2006-03-31	Rs22.37	Rs209.49	x
2007-03-31	Rs26.02	Rs209.49	x
2008-03-31	Rs27.59	Rs209.49	x
2009-03-31	Rs30.22	Rs209.49	x
2010-03-31	Rs33.70	Rs209.49	x
2011-03-31	Rs38.00	Rs209.49	x
2012-03-31	Rs41.75	Rs209.49	x
2013-03-31	Rs44.93	Rs209.49	x
2014-03-31	Rs49.61	Rs209.49	x
2015-03-31	Rs56.30	Rs209.49	x
2016-03-31	Rs63.41	Rs209.49	x
2017-03-31	Rs70.71	Rs209.49	x
2018-03-31	Rs73.25	Rs209.49	x
2019-03-31	Rs72.80	Rs209.49	x
2020-03-31	Rs73.75	Rs209.49	x
2021-03-31	Rs83.45	Rs209.49	x
2022-03-31	Rs98.17	Rs209.49	x
2023-03-31	Rs111.46	Rs209.49	x
2024-03-31	Rs118.46	Rs209.49	x
2025-03-31	Rs119.28	Rs209.49	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Indoco Remedies Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -7.22%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -4.43%
• Asset Turnover: 0.69x
• Equity Multiplier: 2.38x
Recent ROE (-7.22%) is below the historical average (11.74%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2004	24.16%	13.56%	1.04x	1.71x	Rs124.59 Million
2005	14.28%	12.90%	0.68x	1.63x	Rs75.11 Million
2006	15.87%	12.94%	0.78x	1.57x	Rs116.53 Million
2007	18.04%	12.90%	0.94x	1.49x	Rs187.37 Million
2008	16.02%	11.63%	0.94x	1.47x	Rs153.14 Million
2009	10.81%	11.46%	0.63x	1.49x	Rs22.52 Million
2010	13.56%	10.57%	0.83x	1.54x	Rs110.42 Million
2011	14.60%	10.57%	0.86x	1.61x	Rs160.98 Million
2012	12.04%	8.15%	0.87x	1.71x	Rs78.66 Million
2013	10.30%	6.77%	0.91x	1.66x	Rs12.54 Million
2014	12.68%	7.91%	1.00x	1.60x	Rs122.66 Million
2015	15.96%	9.66%	1.01x	1.63x	Rs309.32 Million
2016	14.20%	8.27%	1.04x	1.65x	Rs245.49 Million
2017	11.83%	7.03%	0.92x	1.84x	Rs119.06 Million
2018	6.10%	4.04%	0.82x	1.83x	Rs-263.37 Million
2019	-0.44%	-0.31%	0.75x	1.90x	Rs-689.66 Million
2020	3.55%	2.23%	0.85x	1.87x	Rs-438.40 Million
2021	12.10%	7.64%	0.93x	1.71x	Rs161.46 Million
2022	17.11%	10.29%	1.01x	1.64x	Rs643.36 Million
2023	13.83%	8.67%	0.99x	1.61x	Rs394.25 Million
2024	8.87%	5.51%	0.83x	1.93x	Rs-125.30 Million
2025	-7.22%	-4.43%	0.69x	2.38x	Rs-1.76 Billion

Industry Comparison

This section compares Indoco Remedies Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $23,713,303,062
Average return on equity (ROE) among peers: 8.81%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Indoco Remedies Limited (INDOCO)	Rs9.74 Billion	24.16%	1.57x	$208.80 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$988.60 Million	6.59%	1.36x	$27.93 Million
Aarti Drugs Limited (AARTIDRUGS)	$6.52 Billion	21.67%	1.42x	$371.43 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$19.90 Billion	13.69%	0.46x	$725.68 Million
Abbott India Limited (ABBOTINDIA)	$36.99 Billion	32.48%	0.40x	$5.85 Billion
Ajanta Pharma Limited (AJANTPHARM)	$1.16 Billion	12.69%	1.32x	$3.81 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$6.25 Billion	-40.39%	3.91x	$906.19 Million
Alkem Laboratories Limited (ALKEM)	$88.47 Billion	18.60%	0.59x	$6.98 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$1.46 Billion	16.82%	0.29x	$178.52 Million
Alembic Pharmaceuticals Limited (APLLTD)	$51.90 Billion	11.24%	0.50x	$1.60 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$23.50 Billion	-5.26%	1.65x	$8.73 Billion

About Indoco Remedies Limited

NSE:INDOCO India Drug Manufacturers - Specialty & Generic

Market Cap

$208.80 Million

Rs19.31 Billion INR

Market Cap Rank

#16375 Global

#830 in India

Share Price

Rs209.49

Change (1 day)

-0.01%

52-Week Range

Rs164.00 - Rs339.10

All Time High

Rs511.66